Boston Scientific stock hits all-time high at 107.2 USD

Boston Scientific Corp (NYSE:BSX)’s stock reached an all-time high of 107.2 USD, marking a significant milestone for the medical device company with a market capitalization of $158.5 billion. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with analysts setting price targets ranging from $86 to $135. This achievement reflects a robust 40.16% increase over the past year, showcasing the company’s strong performance and investor confidence. The surge in stock value underscores Boston Scientific’s successful strategies and market position, with impressive revenue growth of 19.4% and an overall Financial Health Score of "GREAT" from InvestingPro. The company continues to innovate and expand its product offerings in the healthcare sector, maintaining low price volatility and operating with moderate debt levels. Investors are closely watching how the company will maintain this momentum amid evolving market conditions. For deeper insights, InvestingPro offers 13 additional tips and a comprehensive research report on Boston Scientific.

In other recent news, Boston Scientific has confirmed its second-quarter and full-year 2025 guidance for both reported and organic sales, along with adjusted earnings per share (EPS). The company recently decided to halt global sales of its Acurate neo2 and Acurate Prime TAVR systems, following regulatory discussions that indicated the need for additional clinical requirements. Despite this discontinuation, Boston Scientific’s TAVR revenue outside the United States showed growth, reaching $214 million in 2024. Piper Sandler maintains an Overweight rating on the company’s stock, highlighting the strong performance of the Farapulse system, which generated approximately $1 billion in its first year of U.S. commercial launch. Analysts from TD Cowen and Citi also maintain positive ratings, with price targets of $115 and $125, respectively, emphasizing the strategic focus on other investment opportunities. Needham analysts see potential growth from products like FARAPULSE and WATCHMAN, which may surpass consensus estimates. The CHAMPION trial results, expected in 2026, are anticipated to be a significant catalyst for the WATCHMAN device. This strategic move by Boston Scientific is also seen as beneficial for competitors like Edwards Lifesciences (NYSE:EW), which may gain increased market share in the aortic valve sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.